Catalyst Pharmaceuticals announced that NCCN Guidelines now include LEMS diagnosis and treatment recommendations for SCLC patients. VGCC antibody testing and neurologic consultation are crucial for accurate LEMS diagnosis in SCLC cases to improve patient outcomes. Approximately 50% of LEMS cases are linked to SCLC, with 3% of SCLC patients developing LEMS. Early LEMS detection can lead to better outcomes for patients undergoing SCLC treatment. The updated guidelines aim to raise awareness and support broader adoption of VGCC diagnostic testing and treatment for cancer-associated LEMS. Catalyst Pharmaceuticals is committed to improving the lives of patients with rare diseases through innovative therapies.

Read more at GlobeNewswire: Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing